Two-year results of treatment with methionyl human growth hormone in children with Turner syndrome. Dutch Growth Hormone Working Group

Acta Paediatr Scand. 1990 Jun-Jul;79(6-7):658-63. doi: 10.1111/j.1651-2227.1990.tb11531.x.

Abstract

Methionyl growth hormone (somatrem) in a daily dosage of 4 IU/m2 body surface area was administered to 16 girls with Turner syndrome. Low dose ethinyl estradiol (0.1 microgram/kg body weight) was added in girls aged 13 years or more. Mean (SD) height velocity increased from 3.4 (0.9) to 7.2 (1.7) and 5.3 (1.3) cm/year in the first and second year, respectively. Bone age advanced 1.8 years over 2 years and predicted adult height was increased. Apart from the occurrence of anti-GH antibodies there were no side effects. In conclusion, somatrem is an efficacious and safe therapy for short stature in Turner syndrome over a period of 2 years. Longer follow-up is needed before conclusions about its effect on final height can be drawn.

MeSH terms

  • Adolescent
  • Body Height / drug effects*
  • Child
  • Female
  • Follow-Up Studies
  • Growth Hormone / administration & dosage
  • Growth Hormone / adverse effects
  • Growth Hormone / analogs & derivatives*
  • Growth Hormone / therapeutic use
  • Hormones / administration & dosage
  • Hormones / adverse effects
  • Hormones / therapeutic use*
  • Human Growth Hormone
  • Humans
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Turner Syndrome / drug therapy*
  • Turner Syndrome / physiopathology

Substances

  • Hormones
  • Recombinant Proteins
  • Human Growth Hormone
  • Growth Hormone